ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platforms
Presentations and Publications
PIPELINE
PARTNERING
NEWS
JOIN US
Our Culture
Benefits
Opportunities
中文
Home
Close
ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platform
Presentations and Publications
PIPELINE
Pipeline
PARTERING
Partnering
NEWS
News
CAREERS
Cultures
Benefit
Opportunities
NEWS
2019
2020
2021
2022
No data
1
2
3
4
5
6
7
8
9
10
11
12
No data
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
27
27
28
29
30
31
No data
SEARCH
NEWARK,U.S.A.andNANJING,China.July31,2023–BiosionUSA,Inc.(Biosion),aglobalclinical-stageR&Dbiotechnologycompany,todayannouncedthephase2studyinitiationfortheevaluationofBSI-045B,ananti-TLSPmAb,in...
2023-07-31
Newark,DE,U.S.andNanjing,China–July5,2023.Biosion,Inc.(Biosion),aglobal,clinical-stagebiotechnologycompany,todayannouncedtheappointmentofFurqanAhmed,PharmD.,astheVicePresidentandHeadofBusinessDe...
2023-07-05
NEWARK,U.S.A.andNANJING,China.May31,2023–ThepartnerofBiosion,Inc.(Biosion),CelldexTherapeutics,Inc.(NASDAQ:CLDX)todayannouncedthatthefirstpatienthasbeendosedinaPhase1studyofCDX-585.CDX-585combin...
2023-06-09
19
2023-09
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
19
2023-09
Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development
19
2023-09
Biosion’s Partner Celldex Therapeutics Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
19
2023-09
Biosion’s Partner Pyxis Oncology Announces First Patient Dosed in Phase 1 Study of PYX-106
19
2023-09
Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
19
2023-09
Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023
上一页
1
2
3
4
下一页
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号
ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platforms
Presentations and Publications
PIPELINE
PARTNERING
NEWS
JOIN US
Our Culture
Benefits
Opportunities
中文
Home
Close
ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platform
Presentations and Publications
PIPELINE
Pipeline
PARTERING
Partnering
NEWS
News
CAREERS
Cultures
Benefit
Opportunities
NEWS
2019
2020
2021
2022
No data
1
2
3
4
5
6
7
8
9
10
11
12
No data
SEARCH
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
2023-07-31
Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development
2023-07-05
Biosion’s Partner Celldex Therapeutics Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
2023-06-09
31
2023-07
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
05
2023-07
Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development
09
2023-06
Biosion’s Partner Celldex Therapeutics Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
31
2023-05
Biosion’s Partner Pyxis Oncology Announces First Patient Dosed in Phase 1 Study of PYX-106
07
2023-05
Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
20
2023-03
Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023
上一页
1
2
3
4
下一页
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号